Pharma partner Presage acquires a clinical candidate of its own

Presage Biosciences, a popular partner for oncology drug developers, is wading into clinical development of its own, in-licensing a candidate and using its technology to spotlight potential combination therapies. The Seattle biotech acquired the rights to voruciclib, an oral CDK inhibitor, from India's Piramal Enterprises. Presage now plans to use its proprietary CIVO technology, which allows for the testing of cancer combinations on living tumors, to identify a path forward with the drug. To date, the company's development platform has helped it land agreements with Takeda and Celgene ($CELG). More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.